Why eFFECTOR Therapeutics Stock Is Heating Up Today
Shares of the clinical-stage cancer company eFFECTOR Therapeutics (NASDAQ: EFTR) are up by a noteworthy 16% as of 10:55 a.m. EDT Thursday morning. Following this latest surge higher, Effector's shares have now gained a whopping 266% since the start of the week.
While the exact cause of the biotech's rapid rise isn't altogether clear, it appears to be the result of big pharma's sudden interest in working with small-cap oncology companies over paying top dollar to acquire well-established commercial entities, along with a healthy dose of interest in the stock on various social media platforms.
Image source: Getty Images.
Source Fool.com
